QR030, Rb

Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Ig Unterklasse:IgG
Immunogen:Synthetic peptide of human WT1
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Nuclear
Kontrolle:Testes, ovarian carcinoma (non-mucinous carcinoma), malignant mesothelioma
Synonyme:WIT 2, WT 1, AWT1, FWT1, GUD, NPHS4, WAGR, Wilms tumor 1, Wilms Tumor, Wilms tumor protein, Wilms' tumor gene, Wilms' tumor protein, WIT2, WT, WT1, WT1_HUMAN, WT33.
Verfügbar in folgenden Ländern:worldwide

WilmsÍ Tumor 1 (WT1) is a transcription factor, which plays a role in the development of the urogenital system. WilmsÍ Tumor is the most common pediatric kidney cancer. WT1 was found in a broad range of adult tumour types, including those derived from mesenchymal, epithelial, neuronal and haematopoietic tissue. The antibody can identify malignant mesothelioma and has been detected in carcinomas of breast, leukemia, ovarian and peritoneal serous carcinoma. WT1 is also used to distinguish desmoplastic small round cell tumors (DSRCT) from other small round cell tumors.


[1] Hastie ND. (2017) Wilms' tumour 1 (WT1) in development, homeostasis and disease. Development. 144(16):2862-2872.
[2] Murphy AJ, Pierce J, de Caestecker C et al. (2014) Aberrant Activation, Nuclear Localization, and Phosphorylation of Yes-Associated Protein-1 in the Embryonic Kidney and Wilms Tumor. Pediatr Blood Cancer. 61(2): 198Ð205.
[3] Rivera MN, Kim WJ, Wells J et al. (2009) The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci U S A. 106(20): 8338Ð8343.
[4] Silberstein GB, Van Horn K, Strickland P et al. (1997) Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc. Natl. Acad. Sci. USA. 94(15): 8132Ð8137.
[5] Wilms M (1899) Die Mischgeschwülste. Leipzig : Verlag von Arthur Georgi.